Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Glaxosmithkline Intellectual Property (no.2) Limited

Brian W Budzik

Jian Jin

David G Cooper

Ian Thomson Forbes

Dongchuan Shi

Graham Walker

Joseph E Pero

Carl A Brooks

Vincenzo Garzya

Brian Griffin Lawhorn

Jay M Matthews

Paul William Smith

Edward J Brnardic

David J Behm

John Jeffrey McAtee

Robert Sanchez

Guosen Ye

Matthew Robert Sender

Jaclyn R Patterson

Lamont Roscoe Terrell

James V Thomas

Linda S Barton

Michael R Palovich

Hilary Schenck Eidam

Dramane Ibrahim Laine

Brent W McCleland

Ralph A Rivero

Clark A Sehon

Krista B Goodman

Gren Z Wang

Pamela A Haile

Andrew Q Viet

Ryan Michael Fox

Chongjie Zhu

Ronggang Liu

Yonghui Wang

Anthony W J Cooper

Terry Vincent Hughes

Nathan A Miller

Tamara Ann Miskowski

Jing Zhang

Haibo Xie

Dimitar B Gotchev

David Gwyn Cooper

The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

TRPV4 antagonists

Compounds of formula (I) and salts and solvates are provided: wherein Ris fluoro, Ris selected from hydrogen, halogen, cyano, Calkyl, Calkyl substituted with one or more fluorine atoms, Calkoxy, and Calkoxy substituted with one or more fluorine atoms; and Ris selected from halogen, cyano, Calkyl, Calkyl substituted with one or more fluorine atoms, Ccycloalkyl, Ccycloalkyl substituted with one or more fluorine atoms, Calkoxy and Calkoxy substituted with one or more fluorine atoms, and Q is hydrogen or Calkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

Compounds which have activity at M1 receptor and their uses in medicine

The present invention relates to a compound of the following formula: where R-R, R, Y, n, m, p, and q are as defined herein. Compounds and compositions of the present invention are useful for the treatment of diseases associated with the overexpression of CCR2.

Spiroindolines as modulators of chemokine receptors

Compounds of formula (I) and salts are provided: wherein Ris selected from hydrogen, halogen, Calkyl, Calkyl substituted with one or more fluorine atoms, Ccycloalkyl, Ccycloalkyl substituted with one or more fluorine atoms, Calkoxy, Calkoxy substituted with one or more fluorine atoms, and cyano, and Q is hydrogen or Calkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

Benzimidazolones which have activity at M1 receptor

Compounds of formula (I) and salts are provided: wherein Ris selected from halogen, Calkyl, Calkyl substituted with one or more fluorine atoms, Calkoxy, Calkoxy substituted with one or more fluorine atoms, and cyano; Ris selected from halogen, Calkyl, Calkyl substituted with one or more fluorine atoms, Ccycloalkyl, Ccycloalkyl substituted with one or more fluorine atoms, Calkoxy, Calkoxy substituted with one or more fluorine atoms, and cyano; and Q is hydrogen or Calkyl. The compounds are Magonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

[object Object]

Compounds of formula (I) and salts are provided: wherein Ris fluoro, Ris selected from hydrogen, halogen, cyano, Calkyl, Calkyl substituted with one or more fluorine atoms, Calkoxy, and Calkoxy substituted with one or more fluorine atoms; and Ris selected from halogen, cyano, Calkyl, Calkyl substituted with one or more fluorine atoms, Ccycloalkyl, Ccycloalkyl substituted with one or more fluorine atoms, Calkoxy and Calkoxy substituted with one or more fluorine atoms, and Q is hydrogen or Calkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.

Growing community of inventors

Collegeville, PA, United States of America

Brian W Budzik